starpharma

Dr. Jackie Fairley CEO

STARPHARMA HOLDINGS LIMITED

ASX:SPL; OTCQX:SPHRY

Biotech Showcase
January 2015

This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this presentation and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.

A global leader in nanoscale polymers (dendrimers)
Potential for multiple and parallel revenue streams

Starpharma's Dendrimer Platform
~100 granted patents





VivaGel® Portfolio

VivaGel® Condom

Bacterial vaginosis

Symptomatic Relief BV

BV Prevention

Ansell

okamoto

Drug Delivery

DEP™ docetaxel

Partner Delivery Programs

DEP™ oxaliplatin

AstraZeneca

Lilly

& other undisclosed Top 10 Pharma companies

Agrochemicals

Improved Agrochemicals ie. Glyphosate

Partner Programs

Gowan
The Go To Company

ISAGRO

ADAMA

>50% Top 10 Ag. companies

Pharmaceutical Development Portfolio – Recent Progress and Plans



Completed

Planned

1. SPA Granted for Phase 3 BV Prevention; Trial underway
2. TGA certification for VivaGel® Condom; Launch
3. Positive early data in DEP™ docetaxel trial
4. BV Symptomatic Relief – Submissions planned imminently

starpharma

Drug Delivery

Starpharma's DEP™ docetaxel: Multiple benefits

- Docetaxel (Taxotere®) is a blockbuster chemotherapeutic
- Docetaxel sales US$3.1B(2012)
- Docetaxel is used in major cancer types including breast, prostate and lung cancer
- Docetaxel is insoluble so Taxotere® incorporates a detergent (polysorbate 80) to solubilize, which is associated with significant toxicity

- Starpharma's patented DEP™ docetaxel is a nanoparticle formulation with multiple advantages compared to Taxotere®
- Patents filed will offer coverage to 2032

- DEP™ docetaxel Phase 1 Trial underway

DEP™ docetaxel vs. Taxotere®

1. Elimination of major dose-limiting toxicity (neutropenia)
2. Improved water solubility allowing removal of toxic components
3. Tumour-targeting
4. Extended half-life
5. Improved efficacy (breast, ovarian, prostate)



DEP™ docetaxel preclinical: Multiple Benefits

Better efficacy *and* less toxicity

Enhanced Safety & Less toxicity

Enhanced Efficacy

Docetaxel + water

DEP™ docetaxel: solubility enhancement >↑ 20,000x polysorbate 80-free

Complete lack of neutropenia with DEP™ docetaxel cf. severe neutropenia for Taxotere®



DEP™ Docetaxel formulation and Taxotere® at equivalent doses (based on docetaxel; 9mg/kg); n=6 rats/group



Tumour Targeting: DEP™ docetaxel > 40 fold greater accumulation in tumour vs. Taxotere®



DEP™ docetaxel: improved pharmacokinetics vs. Taxotere®

DEP™ docetaxel:
Phase 1 Clinical Trial - Encouraging clinical data

- Underway at 3 Australian sites* ; Open label study - allowing progressive results
- Estimated sample: 25-30 cancer patients (various solid tumours)
- DEP™ docetaxel administered every 3 weeks; no steroid pre-treatment

Primary Objectives:

- Establish the maximum tolerated dose (MTD) and dose limiting toxicities (DLT) for DEP™ docetaxel

Secondary Objectives:

- Characterise safety and tolerability
- Characterise pharmacokinetics and define dose for Phase 2 ; Explore preliminary anti-tumour efficacy with CT scans, bone scans, tumour markers etc.

Current Status and Preliminary Findings

- Patients currently being enrolled in dose escalation phase; several dosed with multiple cycles
- Approaching 50% recruitment
- DEP™ docetaxel well tolerated; No neutropenia (docetaxel DLT), nor hair loss observed so far
- Not yet at the MTD but a number of patients have exhibited potential anticancer activity (one with stable disease over > 20 weeks)
- Expansion phase to follow at MTD

*Alfred, Austin Health/Olivia Newton John CC and Royal Brisbane & Women's Hospital

DEP docetaxel® Pharmacokinetics (PK) in humans cf. Taxotere®^

1. <u>Extended duration of exposure with DEP™ docetaxel</u>

– DEP™ docetaxel plasma half-life substantially longer (~8 x) than Taxotere® (~150x longer in the initial, rapid phases of plasma clearance)

<u>2. Increased extent of exposure with DEP™ docetaxel</u>

– DEP™ docetaxel drug exposure (Area Under the Curve /AUC) for total docetaxel, is ~500-800x times greater than an equivalent dose of docetaxel administered as Taxotere®

– reflects the gradual release of docetaxel (DEP™ docetaxel acts as a 'depot' of docetaxel)

<u>3. Reduced peak drug levels with DEP™ docetaxel</u>

– Cmax (peak blood level) of docetaxel is substantially (~50-100 times) lower than the Cmax of an equivalent dose of docetaxel administered as Taxotere®





<u>Example plasma drug levels over time DEP™ docetaxel vs.Taxotere®)</u>

^ *Taxotere® parameters based on published data (Bruno et al, 1996)*

Targeted DEP™ Conjugates (TDCs)

A new approach to drug conjugate design



50% of the top 10 products are antibodies with 2013 sales in excess of **$US38B**

More than **20** ADC drug licensing deals in the past 5 years

The top 3 oncology products are antibodies with combined sales of **US$20B**

Starpharmas Targeted DEP™ conjugates	
Can use small molecule, whole antibody, antibody fragments or antibody mimetics	✓
Bind with high affinity and specificity	✓
Highly efficacious in cancer model in vivo	✓
Flexible and tailored to suit clinical requirements	✓
Homogeneous	✓
Standard Chemistry yielding consistent, reproducible, stable molecules	✓
Platform already in the clinic and demonstrated to be safe and well tolerated	✓

Ovarian cancer model

(SKOV-3 tumour model in NOD SCID mice)



DEP™ insulin – Improved pharmacokinetics (long acting)

Diabetes Market

$43B

Global diabetes market (2013)
(Reuters)



$19B

Global Insulin market^

$9.7B

Long acting (1 day) insulin market:^

- **Lantus $7.6B**
- **Levemir $2.1B**

^2013 MedTrack

DEP™ insulin – Efficacy and Duration of action^





^Glucose Time Course study in the STZ induced diabetic SD rat model after a single subcutaneous injection.

starpharma

The world's first anti-viral condom



VivaGel® Portfolio

VivaGel® condom: A compelling and differentiated product



- Condom coated with SPL's patented antiviral lubricant (VivaGel®)
- **VivaGel®** shown in laboratory studies to **inactivate up to 99.9% HIV, HPV & Herpes**
- Licensed to Ansell and Okamoto (SPL receives royalties on sales)
- Regulatory Certification received in Japan and Australia, NZ other filings in progress
- Product selling in Australia under Lifestyles Dual Protect™ brand
- Extensive international consumer research indicates strong consumer interest
- Branded global condom market: $1.1B

Partner	Market Position/Share	Major Brands
Okamoto Industries (listed on TSE)	• No. 1 in Japan with ~60% Japanese market (the 2nd largest condom mkt. Est. ~US$500M) • Total revenues >US$760M	Skinless® 003® 
Ansell Limited ASX:ANN	• No. 2 globally for condom sales ~ 20% global share of branded condom market (~$1.1B)	Lifestyles® SKYN® ZERO® Manix® 

VivaGel® condom: A compelling and differentiated product

Extensive consumer research of the VivaGel® condom^:

- *Confirms strong interest and purchase intent (~90%)*
- **Strong consumer interest across genders, ages and relationship status**

Percentages shown are the 'top-2-box' scores	TOTAL			18-30 years	31-40 years	41-50 years
Level of interest	85%	88%	82%	87%	86%	82%

"I would buy this product right now if I could….."

"I like the idea of a condom doing more for us than just being a barrier….seems more reassuring to know it's doing extra"

"I would definitely buy this product without a shadow of a doubt….."

VivaGel® Condom Consumer Research

"I think that this product is amazing…... This product is very special and interesting."
"I have rated this product a 5/5 as this is a major breakthrough in the condom market and for world health…"

VivaGel® Condom Consumer Research

Ansell

" Our partnership with Starpharma is a great example of two highly innovative companies working together to bring to market a ground-breaking new sexual health product.
New product development is central to Ansell's business strategy and this highly innovative product is exciting for both companies."

Vice President, Asia Pacific – Sexual Wellness Division

IFL Science posted a story on Dual Protect™- >83,000 Likes; shared > 18,000 times

>2,000 Tweets; including Perez Hilton to ~5.9m followers

^ Formal research conducted in 1800 condom users across USA, Europe, Asia and Sth America

VivaGel®- Bacterial Vaginosis (BV)

Two attractive commercial opportunities

Bacterial Vaginosis:

the most common vaginal infection worldwide

- **~29% women infected in US; up to 51% in some groups**
- **Recurrent BV an issue in 50-60% of BV sufferers**
- **Current therapies have low cure rates and nasty side effects**
- **No approved products for Recurrent BV (R-BV)**



- **"It was like gone almost overnight"**
- **"I would definitely use it again."**
- **"The next day I noticed a huge difference."**
- **"I would use it….I will use it indefinitely…"**

VivaGel® Trial Participants

<u>Product Proposition:</u>

VivaGel® :

- **a <u>non-antibiotic therapy</u>**
- **management of BV symptoms *and***
- **prevention of Recurrent BV**
  - **a selective antimicrobial effect for pathogens that cause BV**
  - **a local effect and is not systemically absorbed**
  - **Large market opportunity for both prevention of recurrent BV and BV Symptomatic Relief**

* Global Data, IMS, various Industry reports,

VivaGel® for Bacterial Vaginosis: Two product opportunities

VivaGel® BV Indications	Drivers of Value: Significant Market Size	Competitive Advantages	Development and Commercial Progress
Prevention of BV Recurrence (Chronic use)	>US$1B	• Unmet need • No Approved • Products • Designed for long term use • Not absorbed	• Phase 3 Trials Underway (SPA) • Late stage License • Partner engagement underway
Symptomatic Relief of BV (Acute use)	US$750-1B	• Rapid onset • Good efficacy • Not absorbed • Non antibiotic • Tolerability benefits	• Phase 3 data: Efficacy at 5-7 days and excellent symptomatic relief • Submissions planned H2 2014 • Partner engagement underway

BV Prevention of Recurrence Phase 3 Program
Two double-blind, multi-centre, randomised trials

SPA granted by FDA

~600 p per trial

~100 sites across USA, EU, Asia, Mexico

"Enriched" R-BV population: Nugent Score 4-10

PERIODIC STUDY VISITS

Primary Endpoint: Recurrence of BV at or by week 16 visit



16-WEEK TREATMENT PERIOD

(DURING WHICH PRIMARY ENDPOINT IS MEASURED)

Dosing regimen: 5g gel every second day at bedtime

SPA granted by FDA on trial design (EMA agreement also gained)

Phase 3 Trials underway with Quintiles

VivaGel®: Symptomatic Relief of BV



VivaGel® (once a day for 7 days):

- Two double-blind trials under IND (250p/trial) demonstrated statistically significant Clinical Cure at the end of treatment (EOT)
- VivaGel® resulted in rapid and sustained relief from symptoms
- Very positive Patient acceptability, excellent safety profile including very low rates of candidiasis
- FDA Treatment endpoint (Cure 2-3 wks following treatment cessation) not met

"It was like gone almost overnight"

"I would definitely use it again."

"The next day I noticed a huge difference."

– VivaGel® Trial Participants

Given the excellent symptomatic relief shown for VivaGel® and positive consumer feedback:

- Symptomatic Relief product submissions are planned H2 2014
- Symptomatic Relief Product under active discussion with a number of interested commercial partners

VivaGel® - Symptomatic Relief
Odour Resolution – % resolved and time to resolution







VivaGel® - 3 Clinical trials

In 3 separate randomised , placebo-controlled trials
VivaGel® consistently provided a statistically significantly greater improvement in odour resolution as compared to placebo

Time to resolution of odour, as reported by patients, showed that VivaGel® resolved odour in 1 day, compared to 7 days for placebo

Starpharma Holdings – Key Financials (A$)

Key Financial Data (Financial Year to 30 June)	FY 2014 AUD $M	FY 2013 AUD $M	FY 2012 AUD $M
Total revenue and income	1.3	2.4	2.9
R&D Tax Incentive # incl. $4.1M from FY2012 expenditure	4.2	8.7#	1.3
Net loss after tax	(14.6)	(5.2)	(13.7)
Cash outflow from operations	(9.8)	(9.8)	(9.8)
Cash at 30 June	24.0^	33.8	42.8

^Cash at 30 Sep 2014 $37.2M
(*excludes* $3.4M SPP & $4.2M R&D Tax incentive)

Analyst Coverage

CIMB · CANACCORD Genuity · BELL POTTER · BBY · PhillipCapital

Expected Short-Medium Term News Flow

VivaGel® Portfolio:

- Regulatory filings for BV Symptomatic Relief product
- Commercialisation agreements for BV Symptomatic Relief product
- Progress VivaGel® Phase 3 BV Prevention of Recurrence trials
- Launches of VivaGel® condom, further approvals/geographic roll-out

DEP™ Delivery technology:

- Further data from DEP™ docetaxel clinical trial
- Complete DEP™ docetaxel clinical trial
- Advance DEP™ oxaliplatin and/or additional DEP™ candidates through preclinical and into clinic
- Partnered program announcements and new deals

Dendrimers in Agrochemicals:

- Advance internal candidates eg. glyphosate (Roundup®) including regulatory-compliant field trials
- Pre-registration activities to support commercialisation
- Partnered program announcements eg. Licences from existing and new deals